PL2846805T3 - Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7 - Google Patents

Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7

Info

Publication number
PL2846805T3
PL2846805T3 PL13793319T PL13793319T PL2846805T3 PL 2846805 T3 PL2846805 T3 PL 2846805T3 PL 13793319 T PL13793319 T PL 13793319T PL 13793319 T PL13793319 T PL 13793319T PL 2846805 T3 PL2846805 T3 PL 2846805T3
Authority
PL
Poland
Prior art keywords
addiction
impulse
treatment
control disorders
pde7 inhibitors
Prior art date
Application number
PL13793319T
Other languages
English (en)
Polish (pl)
Inventor
Gregory A. Demopulos
George A. Gaitanaris
Roberto Ciccocioppo
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/835,607 external-priority patent/US9220715B2/en
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of PL2846805T3 publication Critical patent/PL2846805T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13793319T 2012-05-07 2013-05-07 Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7 PL2846805T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261643611P 2012-05-07 2012-05-07
US13/835,607 US9220715B2 (en) 2010-11-08 2013-03-15 Treatment of addiction and impulse-control disorders using PDE7 inhibitors
EP13793319.8A EP2846805B1 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors
PCT/US2013/039866 WO2013176877A2 (en) 2012-05-07 2013-05-07 Treatment of addiction and impulse-control disorders using pde7 inhibitors

Publications (1)

Publication Number Publication Date
PL2846805T3 true PL2846805T3 (pl) 2019-05-31

Family

ID=49624481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13793319T PL2846805T3 (pl) 2012-05-07 2013-05-07 Leczenie uzależnień i zaburzeń kontroli impulsów za pomocą inhibitorów PDE7

Country Status (10)

Country Link
EP (1) EP2846805B1 (OSRAM)
JP (1) JP2015521177A (OSRAM)
CN (3) CN114984229A (OSRAM)
AU (1) AU2013266793B2 (OSRAM)
CA (1) CA2871151C (OSRAM)
IN (1) IN2014DN10404A (OSRAM)
PL (1) PL2846805T3 (OSRAM)
RS (1) RS58381B1 (OSRAM)
SI (1) SI2846805T1 (OSRAM)
WO (1) WO2013176877A2 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
NZ628055A (en) 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
KR20190040054A (ko) 2016-08-26 2019-04-16 미쓰비시 타나베 파마 코퍼레이션 이환식 함질소 헤테로환 화합물
WO2023243659A1 (ja) * 2022-06-15 2023-12-21 真一 松本 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法
EP4572765A1 (en) * 2022-08-18 2025-06-25 Mitodicure GmbH Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932250B2 (en) * 2004-07-01 2011-04-26 Daiichi Sankyo Company, Limited Thienopyrazole derivative having PDE7 inhibitory activity
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
PL1928438T3 (pl) * 2005-09-26 2013-08-30 Avigen Inc Zastosowanie ibudilastu do leczenia uzależnień od środków odurzających
US8637528B2 (en) * 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EP2139475B1 (en) * 2007-03-27 2014-12-17 Omeros Corporation PDE7 inhibitors for use in the treatment of movement disorders
ES2830073T3 (es) * 2007-04-11 2021-06-02 Omeros Corp Composiciones y métodos para la profilaxis y el tratamiento de adicciones
FR2943673B1 (fr) * 2009-03-27 2013-03-29 Sanofi Aventis Applications therapeutiques de derives de quinazolinedione
FR2944282B1 (fr) * 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
NZ628055A (en) * 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors

Also Published As

Publication number Publication date
CN114984229A (zh) 2022-09-02
CA2871151A1 (en) 2013-11-28
AU2013266793A1 (en) 2014-11-27
WO2013176877A2 (en) 2013-11-28
EP2846805A2 (en) 2015-03-18
SI2846805T1 (sl) 2019-04-30
RS58381B1 (sr) 2019-04-30
AU2013266793B2 (en) 2016-08-04
WO2013176877A3 (en) 2015-06-18
CN104768556A (zh) 2015-07-08
EP2846805A4 (en) 2016-08-10
CN112168972A (zh) 2021-01-05
IN2014DN10404A (OSRAM) 2015-08-14
EP2846805B1 (en) 2018-11-21
CA2871151C (en) 2019-03-26
JP2015521177A (ja) 2015-07-27

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
ZA202108991B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
GB2498121B (en) Treatment device and method of use
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
PT2825161T (pt) Inibidores de ezh2 humana e métodos de uso dos mesmos
IL226203A0 (en) Use of pde7 suppressors and preparations containing them for the treatment of sales and disorders
SG11201504022RA (en) Glutamase inhibitors and method of use
IL241026B (en) A head device for treating and evaluating medical conditions
IL237528B (en) Methods for preventing and treating preeclampsia
EP2870138A4 (en) N-SUBSTITUTED BENZAMIDES AND METHOD OF USE THEREOF
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
ZA201408055B (en) Compositions and methods for the treatment of local pain
GB201217296D0 (en) Method of treatment and/or prevention
EP2707000A4 (en) TREATMENT AND CONTROL OF CNS DISORDERS
SI2827883T1 (sl) Inhibitorji TFPI in postopki uporabe
ZA201607980B (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
IL237887A0 (en) Devices and methods for encouraging hair growth
SI2846805T1 (sl) Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
IL235272B (en) Alfentanil preparation for the treatment of acute pain
HUE043518T2 (hu) Függõség és impulzuskontroll zavarok kezelése PDE-7-inhibitorok alkalmazásával
EP2640468A4 (en) ADMINISTRATIVE AND TREATMENT PROCEDURES
HK1189511A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors